Vascular casted prostheses and methods of forming same for treating biological tissue
Bioremodelable tissue prostheses having a vasculature that is infused with a biomaterial composition.
1. A casted construct for treating damaged biological structures and tissue, comprising:
a tissue prosthesis comprising a reinforced mammalian tissue structure, said mammalian tissue structure comprising sterilized and acellular extracellular matrix (ECM) from a mammalian tissue source,
said mammalian tissue structure further comprising an intact, continuous, reinforced, sterilized and acellular internal vasculature, said internal vasculature and mammalian tissue structure being sterilized and decellularized by perfusion of a sterilant into said internal vasculature,
said vasculature being infused with a biomaterial composition comprising amniotic fluid, wherein an amniotic fluid infused tissue prosthesis is formed, said amniotic fluid comprising amniotic fluid mesenchymal stem cells (AF-MSCs),
said amniotic fluid infused tissue prosthesis being capable of modulating an inflammatory phase of damaged biological tissue, and inducing host cell and tissue proliferation, bioremodeling of said damaged biological tissue, neovascularization and regeneration of new tissue and tissue structures with site-specific structural and functional properties, when said amniotic fluid infused tissue prosthesis is disposed proximate said damaged biological tissue.
2. The casted construct of claim 1 , wherein said sterilized and acellular ECM comprises a crosslinked sterilized and acellular ECM.
3. The casted construct of claim 1 , wherein said mammalian tissue source comprises mammalian tissue selected from the group consisting of small intestine submucosa, urinary bladder submucosa, stomach submucosa, placental tissue, mesothelial tissue, cardiac tissue, kidney tissue, pancreas tissue, and lung tissue.
4. The casted construct of claim 1 , wherein said tissue structure comprises a planar tissue structure.
5. The casted construct of claim 1 , wherein said tissue structure comprises a seamless tubular tissue structure.
6. The casted construct of claim 5 , wherein said seamless tubular tissue structure comprises a segment of mammalian a mammalian structure selected from the group consisting of mammalian intestine, umbilical artery, umbilical vein, ureter, mesenteric vessel and jugular vein.
7. The casted construct of claim 5 , wherein said seamless tubular tissue structure comprises a segment of adolescent small intestine.
8. The casted construct of claim 1 , wherein said biomaterial composition further comprises a first biologically active agent.
9. The casted constrict of claim 8 , wherein said first biologically active agent comprises a first cell selected from the group consisting of a human embryonic stem cell, fetal cardiomyocyte, myofibroblast, and mesenchymal stem cell.
10. The casted construct of claim 8 , wherein said biologically active agent comprises a first growth factor selected from the group consisting of a transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), basic fibroblast growth factor (bFGF), and vascular epithelial growth factor (VEGF).
11. The casted construct of claim 1 , wherein said biomaterial composition further comprises a pharmacological agent.
12. The casted construct of claim 11 , wherein said pharmacological agent comprises a statin selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.
13. The casted construct of claim 11 , wherein said pharmacological agent comprises an anti-inflammatory selected from the group consisting of desoximetasone, diftalone, flazalone, ibuprofen, ibuprofen aluminum, ibuprofen piconol, and rimexolone.
14. The casted construct of claim 1 , wherein said mammalian tissue structure further comprises a second supplemental biologically active agent.
15. The casted construct of claim 14 , wherein said supplemental biologically active agent comprises an exogenously added second cell selected from the group consisting of a human embryonic stem cell, fetal cardiomyocyte, myofibroblast, and mesenchymal stem cell.
16. The casted construct of claim 14 , wherein said supplemental biologically active agent comprises a second growth factor selected from the group consisting of a transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), basic fibroblast growth factor (bFGF), and vascular epithelial growth factor (VEGF).